LLY

776.45

-2.39%↓

JNJ

152.33

+0.12%↑

ABBV

182.26

-2.5%↓

NVO

68.53

+1.17%↑

UNH

308.74

+2.11%↑

LLY

776.45

-2.39%↓

JNJ

152.33

+0.12%↑

ABBV

182.26

-2.5%↓

NVO

68.53

+1.17%↑

UNH

308.74

+2.11%↑

LLY

776.45

-2.39%↓

JNJ

152.33

+0.12%↑

ABBV

182.26

-2.5%↓

NVO

68.53

+1.17%↑

UNH

308.74

+2.11%↑

LLY

776.45

-2.39%↓

JNJ

152.33

+0.12%↑

ABBV

182.26

-2.5%↓

NVO

68.53

+1.17%↑

UNH

308.74

+2.11%↑

LLY

776.45

-2.39%↓

JNJ

152.33

+0.12%↑

ABBV

182.26

-2.5%↓

NVO

68.53

+1.17%↑

UNH

308.74

+2.11%↑

Artivion Inc

Затворен

СекторЗдравеопазване

31.13 1.83

Преглед

Промяна на цената на акция

24 ч

Текуща

Минимум

30.24

Максимум

31.16

Ключови измерители

By Trading Economics

Приходи

16M

-505K

Продажби

1.7M

99M

EPS

-0.012

Марж на печалбата

-0.51

Служители

1,600

EBITDA

2.7M

2.1M

Препоръки

By TipRanks

Препоръки

Силна покупка

12-месечна прогноза

+7.84% upside

Дивиденти

By Dow Jones

Следващи печалби

7.08.2025 г.

Пазарни показатели

By TradingEconomics

Пазарна капитализация

455M

1.5B

Предишно отваряне

29.3

Предишно затваряне

31.13

Настроения в новините

By Acuity

50%

50%

154 / 380 Класиране в Healthcare

Artivion Inc Графика

Миналото представяне не гарантира бъдещи резултати.

Свързани новини

26.06.2025 г., 23:49 ч. UTC

Печалби

Nike Sees Sales Decline Decelerating in 1Q as Turnaround Strategy Plays Out -- 2nd Update

26.06.2025 г., 22:19 ч. UTC

Придобивния, сливания и поглъщания

FTC Clears Alimentation Couche-Tard's $1.57 Billion GetGo Acquisition

26.06.2025 г., 21:30 ч. UTC

Печалби

Nike 4Q Profit, Revenue Slides as Turnaround Strategy Plays Out -- Update

26.06.2025 г., 21:07 ч. UTC

Печалби

Nike 4Q Profit, Revenue Slide as Turnaround Strategy Plays Out

26.06.2025 г., 23:49 ч. UTC

Пазарно говорене

Nikkei May Rise as Fears About Middle East Conflict Ebb -- Market Talk

26.06.2025 г., 23:39 ч. UTC

Пазарно говорене

Gold Edges Lower, Weighed by Stronger-Than-Expected U.S. Data -- Market Talk

26.06.2025 г., 23:34 ч. UTC

Придобивния, сливания и поглъщания

Wesfarmers: Lease Reset Provides Opportunity for Upgrades, Extensions

26.06.2025 г., 23:33 ч. UTC

Придобивния, сливания и поглъщания

Wesfarmers: 62 BWP-Owned Bunnings Sites Get Significantly Longer Leases

26.06.2025 г., 23:32 ч. UTC

Придобивния, сливания и поглъщания

Wesfarmers Will No Longer Receive Earnings From BWP Management

26.06.2025 г., 23:32 ч. UTC

Придобивния, сливания и поглъщания

Wesfarmers to Increase BWP Holding to 23.5% From 22.3%

26.06.2025 г., 23:31 ч. UTC

Придобивния, сливания и поглъщания

Wesfarmers: New BWP Units Priced at 9.2% Premium to Last Close

26.06.2025 г., 23:31 ч. UTC

Придобивния, сливания и поглъщания

BWP to Pay A$100 Mln Cash, A$42.6 Mln in New Units

26.06.2025 г., 23:30 ч. UTC

Придобивния, сливания и поглъщания

Wesfarmers' Bunnings, BWP Trust to Extend and Vary Leases

26.06.2025 г., 23:29 ч. UTC

Придобивния, сливания и поглъщания

Wesfarmers to Sell BWP Management to BWP Trust for A$142.6M

26.06.2025 г., 23:19 ч. UTC

Придобивния, сливания и поглъщания

Andlauer Healthcare Group: Ontario Superior Court of Justice Issues Final Order Approving Sale to UPS

26.06.2025 г., 22:06 ч. UTC

Печалби

Nike's Earnings Were Ugly. But They're Better Than Feared. -- Barrons.com

26.06.2025 г., 21:15 ч. UTC

Печалби

Nike 4Q Profit, Rev Slides as Turnaround Strategy Plays Out -- Update

26.06.2025 г., 21:07 ч. UTC

Придобивния, сливания и поглъщания

Couche-Tard: 35 Stores to Be Divested in Accordance With Regulatory Requirements >ATD.T

26.06.2025 г., 21:07 ч. UTC

Придобивния, сливания и поглъщания

Couche-Tard: GetGo Will Operate as Separate, Stand-Alone Business Unit, Maintain myPerks Loyalty Program >ATD.T

26.06.2025 г., 21:07 ч. UTC

Придобивния, сливания и поглъщания

Couche-Tard: Buyer Will be Approved by the FTC >ATD.T

26.06.2025 г., 21:07 ч. UTC

Печалби

Nike's Earnings Were Ugly. But They're Better Than Feared. -- Barrons.com

26.06.2025 г., 21:06 ч. UTC

Придобивния, сливания и поглъщания

Couche-Tard Agreed to Sell 35 Sites, Including 34 Circle K Locations and One GetGo Property >ATD.T

26.06.2025 г., 21:06 ч. UTC

Придобивния, сливания и поглъщания

Couche-Tard: Transaction Is Expected to Close in the Coming Days >ATD.T

26.06.2025 г., 21:06 ч. UTC

Пазарно говорене

Bank of Mexico Seen Likely to Slow Pace of Rate Cuts -- Market Talk

26.06.2025 г., 21:05 ч. UTC

Придобивния, сливания и поглъщания

COUCHE-TARD RECEIVES FTC CLEARANCE TO COMPLETE ACQUISITION OF GETGO CAFÉ + MARKET >ATD.T

26.06.2025 г., 21:05 ч. UTC

Придобивния, сливания и поглъщания

COUCHE-TARD RECEIVES FTC CLEARANCE TO COMPLETE ACQUISITION OF GETGO CAFÉ + MARKET >ATD.T

26.06.2025 г., 20:52 ч. UTC

Печалби

Nike 4Q Profit, Rev Slide as Turnaround Strategy Plays Out

26.06.2025 г., 20:51 ч. UTC

Печалби

Correct: Nike 4Q Net $211M, Not $200M >NKE

26.06.2025 г., 20:50 ч. UTC

Пазарно говорене

Tech, Media & Telecom Roundup: Market Talk

26.06.2025 г., 20:50 ч. UTC

Пазарно говорене

Basic Materials Roundup: Market Talk

Сравнение с други в отрасъла

Ценова промяна

Artivion Inc Прогноза

Ценова цел

By TipRanks

7.84% нагоре

12-месечна прогноза

Среден 33 USD  7.84%

Висок 35 USD

Нисък 30 USD

Според 5 анализатори от Wall Street, предложили 12-месечна ценова цел за Artivion Inc през последните три месеца.

Консенсусна оценка

By TipRanks

Силна покупка

5 ratings

5

Купи

0

Задържане

0

Продай

Настроение

By Acuity

154 / 380 Класиране в Здравеопазване

Настроения в новините

Neutral

Волатилност

Под средното

Обем новини (RCV)

Над средното

Финанси

Продажбени и админисративни разходи

Оперативни разходи

Печалба преди облагане с данъци

Продажби

Разходи за продажби

Брутна печалба от продажби

Разходи за лихви по дълг

EBITDA

Оперативна печалба

$

Относно Artivion Inc

Artivion, Inc. manufactures, processes, and distributes medical devices and implantable human tissues worldwide. The company provides BioGlue, a polymer consisting of bovine blood protein and an agent for cross-linking proteins for cardiac, vascular, neurologic, and pulmonary procedures; cardiac preservation services; PhotoFix, a bovine pericardial patch; and aortic arch stent grafts including E-vita Open Plus and E-vita Open Neo. It offers E-xtra design engineering systems for the treatment of aortic vascular diseases; E-nside, an off-the-shelf stent graft for the treatment of thoraco-abdominal disease; E-vita THORACIC 3G for the endovascular treatment of thoracic aortic aneurysms; E-ventus BX, a balloon-expandable peripheral stent graft for the endovascular treatment of renal and pelvic arteries; E-liac to treat aneurysmal iliac arteries, and aneurysmal iliac side branches; and E-tegra, a stent graft system for the treatment of infrarenal abdominal aortic aneurysms. In addition, the company offers synthetic vascular grafts for use in open aortic and peripheral vascular surgical procedures; PerClot, an absorbable powdered hemostat for use in surgical procedures; cardiac laser therapy products for angina treatment; CryoVein femoral vein and CryoArtery femoral artery vascular preservation services; On-X prosthetic aortic and mitral heart valves and the On-X ascending aortic prosthesis; CarbonAid CO2 diffusion catheters and Chord-X ePTFE sutures for mitral chordal replacement; and ascyrus medical dissection stents, as well as pyrolytic carbon coating services to medical device manufacturers. It serves physicians, hospitals, and other healthcare facilities, as well as cardiac, vascular, thoracic, and general surgeons. The company was formerly known as CryoLife, Inc. and changed its name to Artivion, Inc. in January 2022. Artivion, Inc. was incorporated in 1984 and is headquartered in Kennesaw, Georgia.